tirzepatide for heart failure Eli Lilly's showed positive results in late-stage trial as treatment SUMMIT: Tirzepatide a 'Huge Win'

These effects are usually mild to moderate and tend to diminish over time as the body adjusts to the medication

Gallbladder problems: Gallstones developed in up to 1.6% of those on Wegovy in clinical trials, compared to 0.7% of those taking placebo

Remarkably, 60% of participants achieved at least 20% weight loss, and 23% lost 30% or more of their body weight

Some foods might be tolerable in tiny quantities but problematic in normal portions

Semaglutides primary strength is its ability to mimic the action of GLP-1, a hormone responsible for reducing appetite, slowing gastric emptying, and stimulating insulin release in response to meals

Overall, the total adverse reactions were similar between the two groups, and no serious adverse events occurred